ERBB2 and cancer: In line with these and other preclinical findings, several ICD inducers were reported to positively interact with numerous immunotherapeutic approaches in patients with cancer, including anti-HER2 anthracycline-based antibody conjugate that potentiated PD-1 blockade in breast cancer61 among other malignancies62, 63.